Glaukos Corporation $GKOS Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System lessened its holdings in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 2.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 64,570 shares of the medical instruments supplier's stock after selling 1,864 shares during the quarter. California State Teachers Retirement System owned approximately 0.11% of Glaukos worth $9,024,303 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Glaukos in the 2nd quarter valued at about $1,333,318,000. Jupiter Topco LLC bought a new stake in Glaukos in the second quarter valued at approximately $679,614,000. Janus Henderson Group PLC grew its stake in Glaukos by 77.2% during the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier's stock worth $575,844,000 after buying an additional 2,329,608 shares in the last quarter. Primecap Management Co. CA acquired a new position in Glaukos during the 2nd quarter worth about $424,969,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Glaukos by 209.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier's stock worth $152,476,000 after purchasing an additional 913,458 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Glaukos Trading Up 0.3%

NYSE:GKOS traded up $0.54 during mid-day trading on Tuesday, hitting $171.63. 185,976 shares of the company's stock were exchanged, compared to its average volume of 850,497. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $191.62. The company has a 50 day simple moving average of $170.49 and a 200-day simple moving average of $138.98. The firm has a market capitalization of $10.12 billion, a P/E ratio of -52.84 and a beta of 0.76.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The company had revenue of $185.61 million for the quarter, compared to the consensus estimate of $150.93 million. During the same quarter last year, the business posted ($0.24) earnings per share. The firm's revenue was up 49.6% compared to the same quarter last year. As a group, research analysts expect that Glaukos Corporation will post -0.32 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Leana Wen sold 525 shares of the business's stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $167.63, for a total transaction of $88,005.75. Following the transaction, the director directly owned 21,092 shares in the company, valued at approximately $3,535,651.96. The trade was a 2.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Gilbert Kliman sold 2,500 shares of the firm's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total value of $475,000.00. Following the transaction, the director directly owned 37,406 shares in the company, valued at approximately $7,107,140. The trade was a 6.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 113,025 shares of company stock valued at $19,600,006 in the last three months. 5.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Citigroup raised their target price on Glaukos from $175.00 to $188.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Wells Fargo & Company raised their price objective on shares of Glaukos from $138.00 to $178.00 and gave the stock an "overweight" rating in a research note on Thursday, July 30th. Wall Street Zen raised shares of Glaukos from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. Weiss Ratings restated a "sell (d-)" rating on shares of Glaukos in a research report on Friday, July 17th. Finally, Truist Financial raised their price objective on Glaukos from $180.00 to $215.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $178.08.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical technology company focused on developing and commercializing products designed to treat glaucoma, corneal disorders and other eye conditions. The company's technologies are intended to provide alternatives to traditional treatments and support earlier intervention in the management of progressive eye disease.

Glaukos is best known for its portfolio of micro-invasive glaucoma surgery products, including the iStent family of implantable devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.